A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism

This trial will enroll adolescents between ages of ≥12 and \<18 years with clinically diagnosed hypoparathyroidism . The purpose of the study is to see how well treatment with once-daily palopegteriparatide works and how safe it is. At least 12 participants will receive palopegteriparatide for 234 weeks. This trial will be conducted in Europe.

NCT Number	NCT07706764
Lead Sponsor	Ascendis Pharma A/S
Conditions	Hypoparathyroidism
Enrollment	12 participants
Start Date	2026-04-22
Primary Completion	2027-08 (estimated)
Study Completion	2031-08 (estimated)
Updated on ClinicalTrials.gov	2026-07-28